Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 104

Results For "UP"

7661 News Found

Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma
News | February 22, 2022

Infinity Holding Group to acquire 43.7 per cent stake in Jagsonpal Pharma

The transaction as well as the open offer is expected to be completed by June this year.


IFF to acquire contract manufacturer of dietary supplements Health Wright Products
News | February 22, 2022

IFF to acquire contract manufacturer of dietary supplements Health Wright Products

The sale is expected to close in the first quarter of 2022


Corbevax receives EUA for 12-18 age group
News | February 21, 2022

Corbevax receives EUA for 12-18 age group

It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


Natco Q3FY22 PAT up 27% to Rs 80 Cr
News | February 19, 2022

Natco Q3FY22 PAT up 27% to Rs 80 Cr

The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.


Evonik invests in start-up to improve patient recovery after open-chest surgery
Startup | February 18, 2022

Evonik invests in start-up to improve patient recovery after open-chest surgery

Evonik invests in start-up to improve patient recovery after open-chest surgery


AptarGroup reported 2021 sales at US $3.23 billion
News | February 18, 2022

AptarGroup reported 2021 sales at US $3.23 billion

AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.


Rajiv Gupta to retire as chairman of Avantor
News | February 17, 2022

Rajiv Gupta to retire as chairman of Avantor

Gupta to retire at the end of his current term on May 12, 2022, after more than a decade of service, during which time Avantor has transformed into a global life sciences leader


USFDA approves Lupin’s Supplemental New Drug Application for Solosec
Drug Approval | February 17, 2022

USFDA approves Lupin’s Supplemental New Drug Application for Solosec

The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV


USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi
Biotech | February 17, 2022

USFDA accepts for Priority Review Bristol Myers Squibb’s Supplemental BLA for Breyanzi

Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years